Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1029-1033. doi: 10.1051/medsci/2019204. Epub 2020 Jan 6.

[Rheumatology, the multitude of options].

[Article in French; Abstract available in French from the publisher]

Author information

1
Département de rhumatologie, Université et CHU de Montpellier ; UMR 5535, Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France.
2
Université de Tours, EA 7501, Groupe insuffisance cardiaque et cardiomyopathie (GICC), CHRU de Tours, Service de rhumatologie, Tours, France.

Abstract

in English, French

The number of therapeutic antibodies available in rheumatology increases every year, mainly indicated in chronic inflammatory rheumatisms and other immune-mediated inflammatory diseases. The choice between all these monoclonal antibodies depends on their specificities, patients and diseases characteristics. Until now, there is no reliable biomarker, predictive of response for specialized medicine purpose. Today, therapeutic drug monitoring and anti-drug antibodies testing can help to better adapt the dose of the drug and to help in the decision to switch to another biological drug according to the activity of the inflammatory disease.

PMID:
31903914
DOI:
10.1051/medsci/2019204

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center